Mesa Laboratories
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +43.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 110.3x | Better than 3% |
| Forward P/E | 53.3x | Better than 7% |
| Price / Sales | 3.1x | Better than 40% |
| P/E vs own 5-yr range | 59th pctl | Better than 50% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 4.4% | Better than 44% |
| Net income CAGR (3Y) | 93.3% | Better than 95% |
| Free cash flow CAGR (3Y) | 19.1% | Better than 63% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 63.5% | Better than 77% |
| Operating margin | 7.4% | Better than 43% |
| Net margin | 2.7% | Better than 35% |
| Return on equity | 3.9% | Better than 34% |
| Return on invested capital | 3.8% | Better than 40% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 2.7% | Better than 79% |
| 6-month return | 18.1% | Better than 81% |
| 12-month return (ex latest month) | 83.4% | Better than 93% |
| Distance below 52-week high | 11.4% | Better than 80% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.7x | Better than 48% |
| Debt to assets | 36.3% | Better than 31% |
| Interest coverage | 2.1x | Better than 37% |
| Free cash flow / net income | 589.7% | Better than 94% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 133.41
- Open
- 131.62
- Day range
- 126.73 - 134.00
- Avg price
- 129.98
- Volume
- 76.02K
- Turnover
- 9.88M
- Turnover ratei
- 1.53%
- Volume ratioi
- 0.81
- Amplitudei
- 5.45%
- 52-week rangei
- 69.73 - 144.35
Valuation
- P/Ei
- 105.73
- P/E (TTM)i
- 110.28
- P/Bi
- 3.70
- EPSi
- 1.21
- Book value / shi
- 34.62
- Net profit
- 6.80M
- Net assets
- 194.59M
Share structure
- Market cap
- 719.03M
- Float capi
- 635.59M
- Shares out
- 5.62M
- Float sharesi
- 4.97M
Dividend & listing
- Div yield (TTM)i
- 0.50%
- Dividend (TTM)
- 0.64
- Listing date
- --
11.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+630.11K net over the window
Short interest
- Shares short
- 377.16K
- % of floati
- 6.74%
- Days to coveri
- 4.68
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Mesa Laboratories (MLAB)?
Mesa Laboratories last traded at 127.93. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Mesa Laboratories's market cap?
About 719.03M.
What is the P/E ratio of Mesa Laboratories?
The trailing twelve-month P/E is 110.28. The Valuation tab shows it against the stock's own five-year range.
Does Mesa Laboratories pay a dividend?
Yes. The trailing dividend yield is 0.50%. Per-share dividends have risen or held for 7 straight years through 2025. See the Dividends tab for the full payment history.
Is Mesa Laboratories a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 150.00, which implies 17.3% upside from the current price. This is not investment advice.
What is Mesa Laboratories's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Mesa Laboratories a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mesa Laboratories discussion 0 comments